Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

8.610 -0.050 (-0.58%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 30, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 965,298
Open 8.670
Bid (Size) 8.620 (1)
Ask (Size) 9.500 (16)
Prev. Close 8.660
Today's Range 8.600 - 9.055
52wk Range 6.850 - 54.74
Shares Outstanding 122,816,314
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NeoGenomics and Liquid Biopsy Subsidiary Inivata and Collaborators to Present New Data at ESMO Congress 2022
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For August 26, 2022
Upgrades 
Via Benzinga

Performance

YTD
-75.57%
-75.57%
1 Month
-14.50%
-14.50%
3 Month
-6.82%
-6.82%
6 Month
-31.61%
-31.61%
1 Year
-82.24%
-82.24%

More News

Read More
Turnaround For This Cancer Genetics Testing Firm Could Take Years, Analyst Says While Downgrading Stock
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2022
Via Benzinga
NeoGenomics: Q2 Earnings Insights
Via Benzinga
What 4 Analyst Ratings Have To Say About NeoGenomics
Via Benzinga
NeoGenomics: Q2 Earnings Insights
Via Benzinga
Target To $200? Here Are 5 Other Price Target Changes For Thursday
Via Benzinga
NeoGenomics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
Earnings Scheduled For August 12, 2022
Via Benzinga
NeoGenomics Reports Revenue of $125 Million in the Second Quarter
Via ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
Via ACCESSWIRE
NeoGenomics Announces Chief Executive Officer Appointment
From NeoGenomics, Inc.
Via AccessWire
NeoGenomics Schedules its Second Quarter 2022 Earnings Release for August 9, 2022
From NeoGenomics, Inc.
Via AccessWire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Continues Its Investigation of NeoGenomics, Inc. (NEO) on Behalf of Investors
From Law Offices of Frank R. Cruz
Via Business Wire
NeoGenomics Liquid Biopsy Subsidiary Inivata Announces New Data Demonstrating Clinical Potential of the RaDaR(TM) MRD Test in HR+ HER2- Breast Cancer
From NeoGenomics, Inc.
Via AccessWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
NeoGenomics To Participate In Multiple Upcoming Institutional Investor Conferences
From NeoGenomics, Inc.
Via AccessWire
Analyst Ratings for NeoGenomics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2022
Via Benzinga
NeoGenomics Receives CAP Certification in their Suzhou China Pharma Services Laboratory
From NeoGenomics, Inc.
Via AccessWire
NASDAQ:NEO Investor Alert: Investigation over Possible Wrongdoing at NeoGenomics, Inc.
Via SBWire
Lost Money in NeoGenomics, Inc.?
From Gibbs Law Group
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.